Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel Free MIST Stock Alerts

Milestone Pharmaceuticals (MIST) Competitors

Milestone Pharmaceuticals logo
$0.92 0.00 (-0.41%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$0.92 +0.00 (+0.46%)
As of 09/18/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

MIST vs. RLMD, SPRY, AVIR, CGC, and TTRX

Should you buy Milestone Pharmaceuticals stock or one of its competitors? Milestone Pharmaceuticals's main competitors and comparable companies include Relmada Therapeutics (RLMD), ARS Pharmaceuticals (SPRY), Atea Pharmaceuticals (AVIR), Canopy Growth (CGC), and Turn Therapeutics (TTRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Milestone Pharmaceuticals compare to Relmada Therapeutics?

Milestone Pharmaceuticals (NASDAQ:MIST) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

In the previous week, Relmada Therapeutics had 4 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 4 mentions for Relmada Therapeutics and 0 mentions for Milestone Pharmaceuticals. Relmada Therapeutics' average media sentiment score of 1.10 beat Milestone Pharmaceuticals' score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Milestone Pharmaceuticals Neutral
Relmada Therapeutics Positive

86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are owned by institutional investors. 5.0% of Milestone Pharmaceuticals shares are owned by insiders. Comparatively, 14.5% of Relmada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Relmada Therapeutics' return on equity of -47.52% beat Milestone Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Milestone PharmaceuticalsN/A -288.33% -58.27%
Relmada Therapeutics N/A -47.52%-43.97%

Milestone Pharmaceuticals presently has a consensus target price of $6.40, suggesting a potential upside of 598.84%. Relmada Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 191.26%. Given Milestone Pharmaceuticals' higher probable upside, equities analysts plainly believe Milestone Pharmaceuticals is more favorable than Relmada Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Milestone Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.71
Relmada Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.75

Milestone Pharmaceuticals has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market.

Relmada Therapeutics has lower revenue, but higher earnings than Milestone Pharmaceuticals. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Milestone Pharmaceuticals$1.55M73.56-$63.06M-$0.69N/A
Relmada TherapeuticsN/AN/A-$57.38M-$0.90N/A

Summary

Relmada Therapeutics beats Milestone Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Milestone Pharmaceuticals compare to ARS Pharmaceuticals?

Milestone Pharmaceuticals (NASDAQ:MIST) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

Milestone Pharmaceuticals currently has a consensus price target of $6.40, suggesting a potential upside of 598.84%. ARS Pharmaceuticals has a consensus price target of $26.40, suggesting a potential upside of 542.34%. Given Milestone Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Milestone Pharmaceuticals is more favorable than ARS Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Milestone Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.71
ARS Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, ARS Pharmaceuticals had 16 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 16 mentions for ARS Pharmaceuticals and 0 mentions for Milestone Pharmaceuticals. Milestone Pharmaceuticals' average media sentiment score of 0.00 beat ARS Pharmaceuticals' score of -0.07 indicating that Milestone Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Milestone Pharmaceuticals Neutral
ARS Pharmaceuticals Neutral

Milestone Pharmaceuticals has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -184.24%. ARS Pharmaceuticals' return on equity of -256.67% beat Milestone Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Milestone PharmaceuticalsN/A -288.33% -58.27%
ARS Pharmaceuticals -184.24%-256.67%-69.63%

86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 5.0% of Milestone Pharmaceuticals shares are owned by company insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Milestone Pharmaceuticals has higher earnings, but lower revenue than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Milestone Pharmaceuticals$1.55M73.56-$63.06M-$0.69N/A
ARS Pharmaceuticals$84.28M4.85-$171.30M-$2.18N/A

Milestone Pharmaceuticals has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

Summary

Milestone Pharmaceuticals beats ARS Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Milestone Pharmaceuticals compare to Atea Pharmaceuticals?

Milestone Pharmaceuticals (NASDAQ:MIST) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment.

Milestone Pharmaceuticals has higher revenue and earnings than Atea Pharmaceuticals. Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Milestone Pharmaceuticals$1.55M73.56-$63.06M-$0.69N/A
Atea PharmaceuticalsN/AN/A-$158.35M-$2.08N/A

In the previous week, Atea Pharmaceuticals had 1 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 1 mentions for Atea Pharmaceuticals and 0 mentions for Milestone Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.57 beat Milestone Pharmaceuticals' score of 0.00 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Milestone Pharmaceuticals Neutral
Atea Pharmaceuticals Positive

Atea Pharmaceuticals' return on equity of -64.25% beat Milestone Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Milestone PharmaceuticalsN/A -288.33% -58.27%
Atea Pharmaceuticals N/A -64.25%-57.12%

86.2% of Milestone Pharmaceuticals shares are held by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are held by institutional investors. 5.0% of Milestone Pharmaceuticals shares are held by company insiders. Comparatively, 21.6% of Atea Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Milestone Pharmaceuticals presently has a consensus target price of $6.40, suggesting a potential upside of 598.84%. Atea Pharmaceuticals has a consensus target price of $7.00, suggesting a potential upside of 31.33%. Given Milestone Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Milestone Pharmaceuticals is more favorable than Atea Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Milestone Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.71
Atea Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.33

Milestone Pharmaceuticals has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market.

Summary

Milestone Pharmaceuticals beats Atea Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Milestone Pharmaceuticals compare to Canopy Growth?

Milestone Pharmaceuticals (NASDAQ:MIST) and Canopy Growth (NASDAQ:CGC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

Milestone Pharmaceuticals has a net margin of 0.00% compared to Canopy Growth's net margin of -65.33%. Canopy Growth's return on equity of -21.91% beat Milestone Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Milestone PharmaceuticalsN/A -288.33% -58.27%
Canopy Growth -65.33%-21.91%-14.34%

86.2% of Milestone Pharmaceuticals shares are held by institutional investors. Comparatively, 3.3% of Canopy Growth shares are held by institutional investors. 5.0% of Milestone Pharmaceuticals shares are held by insiders. Comparatively, 0.4% of Canopy Growth shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Milestone Pharmaceuticals has higher earnings, but lower revenue than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Milestone Pharmaceuticals$1.55M73.56-$63.06M-$0.69N/A
Canopy Growth$251.01M1.67-$190.29M-$0.45N/A

Milestone Pharmaceuticals has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market. Comparatively, Canopy Growth has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

In the previous week, Canopy Growth had 10 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 10 mentions for Canopy Growth and 0 mentions for Milestone Pharmaceuticals. Canopy Growth's average media sentiment score of 0.80 beat Milestone Pharmaceuticals' score of 0.00 indicating that Canopy Growth is being referred to more favorably in the news media.

Company Overall Sentiment
Milestone Pharmaceuticals Neutral
Canopy Growth Positive

Milestone Pharmaceuticals currently has a consensus target price of $6.40, suggesting a potential upside of 598.84%. Given Milestone Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Milestone Pharmaceuticals is more favorable than Canopy Growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Milestone Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.71
Canopy Growth
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20

Summary

Milestone Pharmaceuticals beats Canopy Growth on 11 of the 17 factors compared between the two stocks.

How does Milestone Pharmaceuticals compare to Turn Therapeutics?

Turn Therapeutics (NASDAQ:TTRX) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Turn Therapeutics currently has a consensus target price of $9.00, indicating a potential downside of 39.76%. Milestone Pharmaceuticals has a consensus target price of $6.40, indicating a potential upside of 598.84%. Given Milestone Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Milestone Pharmaceuticals is more favorable than Turn Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Turn Therapeutics
2 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.20
Milestone Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.71

In the previous week, Turn Therapeutics had 8 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 8 mentions for Turn Therapeutics and 0 mentions for Milestone Pharmaceuticals. Turn Therapeutics' average media sentiment score of 0.56 beat Milestone Pharmaceuticals' score of 0.00 indicating that Turn Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Turn Therapeutics Positive
Milestone Pharmaceuticals Neutral

86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 5.0% of Milestone Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Turn Therapeutics' return on equity of -230.84% beat Milestone Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Turn TherapeuticsN/A -230.84% -53.19%
Milestone Pharmaceuticals N/A -288.33%-58.27%

Turn Therapeutics has higher earnings, but lower revenue than Milestone Pharmaceuticals. Turn Therapeutics is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Turn TherapeuticsN/AN/A-$3.19M-$0.29N/A
Milestone Pharmaceuticals$1.55M73.56-$63.06M-$0.69N/A

Summary

Milestone Pharmaceuticals beats Turn Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Milestone Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MIST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MIST vs. The Competition

Export
MetricMilestone PharmaceuticalsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$114.49M$12.48B$7.26B$13.14B
Dividend YieldN/A2.63%2.57%12.30%
P/E Ratio-1.33797.25275.7925.40
Price / Sales73.56950.97695.58114.47
Price / CashN/A88.4477.4251.66
Price / Book2.3510.5310.466.33
Net Income-$63.06M$2.82B$3.49B$358.33M
7 Day Performance-6.56%1.69%0.59%1.12%
1 Month Performance-15.20%0.83%-2.01%-2.67%
1 Year Performance-52.30%3.90%18.09%6.01%

Milestone Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MIST
Milestone Pharmaceuticals
1.9748 of 5 stars		$0.92
-0.4%		$6.40
+598.8%		-53.0%$114.49M$1.55MN/A38
RLMD
Relmada Therapeutics
2.5445 of 5 stars		$4.47
+0.7%		$12.00
+168.5%		+149.7%$474.04MN/AN/A17
SPRY
ARS Pharmaceuticals
1.6975 of 5 stars		$4.42
-1.7%		$26.40
+496.9%		-58.6%$439.16M$116.93MN/A200
AVIR
Atea Pharmaceuticals
2.1775 of 5 stars		$5.20
-2.3%		$7.00
+34.7%		+79.5%$422.76MN/AN/A55
CGC
Canopy Growth
1.0091 of 5 stars		$0.93
-1.0%		N/A-32.3%$420.10M$293.63MN/A1,128

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:MIST) was last updated on 9/19/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel